We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Oct 8, 2018

7th Congress of the European Academy of Paediatric Societies

POSTINFECTIOUS BRONCHIOLITIS OBLITERANS (BO) IN CHILDREN

postinfectious

bronchiolitis

corticosteroid

occasional antibiotic

azithromycin

Abstract

25

Views

25

Views

Abstract

Fullscreen

thumbnail

Keywords

postinfectious

bronchiolitis

corticosteroid

occasional antibiotic

azithromycin

Abstract

Intoduction: Postinfectious bronchiolitis obliterans (BO) in children is a rare yet a severe complication after a respiratory viral infection of the first age. It is due to a chronic inflammatory process with characteristic features of fibrosis of terminal and distal bronchioles. Patients and methods: In our retrospective study including children admitted to the service of paediatrics of Mahdia over a period of 31 years. Results: twenty six cases of BO were diagnosed characterized by a predominance of females .The average age of the diagnosis was in 49,2 months. The risk factors are essentially related to the early age (3-month-old in the first respiratory infection) and to the severity of the infection. The symptoms were polymorphic: repetitive respiratory infections in 50 %,other characteristically symptoms such as dyspnea or cough (34,61 %),some may also present severe asthma (26,92 %). Chest CT scan noted the mosaic pattern of perfusion in 12 % of the cases. THE spirometry demonstrated airflow obstruction which is not or little reversible. The evolution was favorable in 76,9 % of the cases which were either under an intermittent oral corticosteroid therapy or under an azithromycine for a long-term and with low doses. The occasional antibiotic treatment was effective against the infectious exacerbations due to bronchial dilatation. Conclusion: the BOPI is a rare but grave disease requiring an early and adequate care especially with the presence of risk factors. The oral intermittent corticosteroid therapy and the azithromycin with prolonged low dose seem to be the most effective therapy to protect the respiratory future of the child.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.